HDAC9 and mantle cell lymphoma: Importantly, inhibition of HDAC and PI3K signaling together with CUDC-907, a dual HDAC-PI3K inhibitor showed profound activity in ibrutinib-resistant MCL cell lines and PDX mouse models [175].